In a previous study, yeast RNA polymerase II(B) was affinity labeled with two nucleotide derivatives (III and VIII) (1). In both cases, the labeled site was localized to the C-termlnal part of the B150 subunlt. The potential target lysyl residues of derivative III were mapped to the conserved domain H, between Asn946 and Met999. In the present work, we have mutagenized to arglnlne the five lyslnes present in domain H. Three lysines can be replaced, individually or simultaneously, without affecting cell growth, and each mutated enzyme can still be affinity labeled. Hence one or both of the other two lysyl residues, Lys979 and Lys987, is the target of the affinity reagent. These two lysines were each found to be essential for cell viability. Derivative VIII labeled another domain in addition to domain H. Supported by analogous results obtained for E.coll RNA polymerase using derivative VIII (2), we hypothesized that the second domain labeled by this derivative In the B150 subunit was domain I. Mutagenesis of the unique lysine present in domain I demonstrated that Lys 1102 was the target of derivative VIII. These results indicate that in both prokaryotlc and eukaryotic RNA polymerases, domains H and I are in close proximity and participate to the active site.
INTRODUCTION
Eukaryotic nuclear RNA polymerases are composed of two large subunits, homologous to bacterial jS and /S' subunits, and a set of 10 to 12 smaller polypeptides. The two large subunits are involved in the polymerization process and in the binding of the DNA template and the nascent RNA chain (3, 4, 5) . Grachev et al. (6) developed a highly selective affinity labeling technique to investigate the active site of RNA polymerases. The procedure uses a nonradioactive nucleotide derivative modified at its terminal phosphate group with a radical carrying an aldehyde function which reacts with lysyl residues. Specific labeling occurs when RNA polymerase with a nucleotide derivative cross-linked in its active center catalyses phosphodiester bond formation with a radioactive ribonucleoside triphosphate. Mapping of the affinity labeled site in E.coli RNA polymerase demonstrated that the target residues of the affinity reagents were localized to two conserved domains (H and I) in the C-terminal part of the /3 subunit (2).
Riva et al. (7) , using different ATP derivatives, localized the nucleotide binding site of the three yeast RNA polymerases in the second largest subunit homologous to the bacterial /3 subunit. When using derivatives HI and VIII, the nucleotide binding site of the enzyme II was mapped to the C-terminal part of B150 subunit between Asn946 and Met999 (1) . Derivative VIH also labeled a second region whose position was not determined.
To identify the affinity labeled amino-acids of RNA polymerase n, we mutagenized the lysyl residues present in the two labeled domains. We show that at least one of the two conserved residues Lys979 or Lys987 is labeled in domain H and that lysine 1102 is the target of derivative Vm in domain I.
MATERIALS AND METHODS

Strains and plasmids
Yeast strain Z96 (ura3-52, his3A2OO, Ieu2-3,112, rpb2A297::HIS3 [pRP214 (LEU2 RPB2)]) was obtained from R.A. Young (8) . pBluescript was from Stratagene and pUN75 (ARS1, CEN4, URA3) was from Elledge and Davis (9) .
Oligonucleotides
Oligonucleotides were synthesized by the phosphoramidite method using an Applied Biosystems 38OB DNA synthesizer. The oligodeoxynucleotides used were: to change Lys962 to Arg, 5'ATGGGTTAAGGTTTGTC 3' (mismatch underlined); to change Lys965 to Arg, 5'TGTCAQAGTTCGTGTAA 3'; to change Lys972 to Arg, 5'ACTACAAQGATTCCTCA 3'; to change Lys979 to Arg, 5TGGTGACAQATTTGCTTC 3'; to change Lys987 to Arg, 5'CACGGTCAAAQGGGTACT 3'; to change Lysl 102 to Arg, 5'GGATGACAGGATACATGCC 3'; to change simultaneously Lys962, Lys965 and Lys972 to Arg, 5'ATGGGTTAAQGTTTGTCAQAGTTCG 3' and 5'ACTA-CAAGGATTCCTCA 3'. These oligodeoxynucleotides were phosphorylated in vitro at their 5' ends by T4 kinase before site directed mutagenesis.
Piasmid construction and mutagenesis pLS76 and pLS114 are respectively pBluescript SK + and pUN75 plasmids containing the entire RPB2 gene where two restriction sites (Kpnl and Spel) have been introduced in the open reading frame without any alteration of B150 amino acid sequence (10) .
For site directed mutagenesis of Lys962, 965, 972, 979 and 987, the 1060 bp Xhol-Kpnl fragment from pLS76 was introduced between the Xhol and Kpnl sites of pBluescript SK + , to give pLS119. For site directed mutagenesis ofLysllO2, the 566 bp KpnI-Spel fragment from pLS76 was introduced between tiie Kpnl and Spel sites of pBluescript SK + , to give pLS83. Single-stranded DNA from plasmids pLS119 and pLS83 was produced according to Vieira and Messing (11) , and oligonucleotides were used in an oligonucleotide-directed in vitro mutagenesis system (Bio-Rad) under the conditions described by the supplier. After mutagenesis, the 1060 bp Xhol-Kpnl or the 566 bp KpnI-Spel fragments were sequenced by the dideoxynucleotide chain-termination method (12) in order to confirm that the expected change had been introduced without additional mutation.
To introduce the mutations into the RPB2 gene, either the XholKpnl or the KpnI-Spel fragment of pLSl 14 was replaced by the corresponding mutated fragment to give pLS151 (K962R), pLS152 (K965R), pLS153 (K972R), pLS147 (K979R), pLS129 (K987R), pLS173 (K962K965K972RRR) and pLS121 (K1102R). Mutations are indicated by the single-letter designation of the amino acid changed followed by its position and by the substituted residue.
Yeast transformations
Yeast strains were transformed by the lithium acetate polyethylene glycol procedure (13) . The plasmid shuffling method described by Mann et al. (14) was used to determine the effects of the mutations on the yeast growth. Briefly, plasmids harboring the mutated RPB2 gene were introduced into haploid yeast cell earring a disrupted chromosomal copy of RPB2 and a resident wild-type copy of RPB2 on plasmid pRP214 (8) . The phenotype of the cells that received the mutated plasmid was examined in the presence or absence of the resident plasmid.
RNA polymerase purification
Yeast RNA polymerase n from wild-type and single mutant strains was purified as described. Crude extracts were prepared according to Sawadogo et al. (15) from 20g of cells and were incubated with phosphocellulose (Whatman PI 1) at 4°C during 30 min in Tris 20 mM, £-mercaptoethanol lOmM, EDTA 0.5 mM, glycerol 10% at pH8.0 (BI buffer) with ammonium sulfate 50 mM. The flow through fraction was loaded on a heparinultrogel column (TBF) in BI buffer containing 100 mM ammonium sulfate. Elution was performed at 300 mM ammonium sulfate in buffer BI. The eluate was diluted twice and loaded on a Mono Q HR 5/5 column (Pharmacia). A linear gradient was developed at 0,8 ml/min during 25 min between 150 mM ammonium sulfate and 600 mM ammonium sulfate in buffer BI. Fractions containing RNA polymerase II activity were pooled and loaded on a Phenyl TSK-5PW column (Bio Rad) at an ionic strength of 1 M ammonium sulfate in buffer BI. Proteins were eluted with a linear gradient of 45 min between 1 M ammonium sulfate and 0 M ammonium sulfate in Hepes 50 mM pH8.0, 10% glycerol . Fractions (500 y.\) containing the highest RNA polymerase II activity were subsequently used in the affinity labeling experiments. Yeast RNA polymerase II from the triple mutant strain was purified according to Sawadogo et al. (15) until the glycerol gradient step. Because of the low amount of RNA polymerase which can be purified from this strain, a concentration step was required before affinity labeling. Concentration and desalting of the RNA polymerase II were performed on a Mono Q column (Pharmacia) which was developed with a linear gradient from 50 mM NaCl to 1 M NaCl in Hepes 25 mM pH 8.0, 0-mercaptoethanol 1 mM over a period of 30 min at 100 jtl/min, using a Smart System (Pharmacia). Fractions of 50 fil were collected and assayed for RNA polymerase II activity. The most concentrated fraction contained 320 /ig/ml of RNA polymerase II.
Affinity labeling
RNA polymerase II (= 1,5 /tg) from wild-type and mutant strains was incubated for 30 min at 30°C in 9 fi\ of a mixture containing 1 mM derivative HI or 2.5 mM derivative VHI (see scheme 1), 10 mM Hepes/NaOH pH7.9, 75 mM KC1, 1 mM dithiothreitol and 2.5 mM MnCl 2 -Then 1 ^1 of 100 mM NaBRt was added and the incubation was continued for 30 min. The covalentiy modified enzyme was labeled by initiating RNA synthesis with 0.1 nM [a-^PJ-UTP (3000 Ci/mmole, Amersham) in presence of 1 ng of denatured calf thymus DNA for 30 min at 30°C. The samples were further treated for 20 min at 30°C with RNAse A (8 /tg/ml) and DNAse I (8 /tg/ml) before analysis by SDS-PAGE.
Hydroxylamine cleavage of B150 in gel pieces
Hydroxylamine cleavage of proteins in gel pieces was done according to Saris et al. (16) in single hit cleavage conditions (i.e. no internal peptide was obtained in these conditions). Briefly, the labeled B150 bands in the dried gel were excised after autoradiography. Gel pieces were swollen in 5% methanol, the paper was peeled off and SDS was removed by washing 3 times for 10 min at room temperature in 5% methanol. Gel pieces were dried in a Speed Vac concentrator (Savant) for 15 min at room temperature, submerged in 200 yl of either the reaction or the control mixture and incubated at 45°C for 20 min. The reaction mixture contained 2 M hydroxylamine hydrochloride (Fluka), 6 M guanidine hydrochloride (Pierce), 15 mM Tris and pH was adjusted to 9.5 with 4.5 M lithium hydroxyde. The control mixture did not contain hydroxylamine. To stop the reaction, gel pieces were washed by two quick changes of 5% methanol and then were more extensively rinsed with two changes (15 min) of 5% methanol. Gel pieces were then dried as indicated above, and incubated in 50 /tl of electrophoresis sample buffer at 100°C for 5 min. Gel pieces and buffer were applied to a polyacrylamide gel for analysis of protein fragments by electrophoresis in denaturing conditions.
Sodium Dodecyl Sulfate Electrophoresis in Polyacrylamide Slab Gels
Electrophoresis in polyacrylamide slab gels in the presence of SDS was performed according to Laemmli (17) . Subunits of yeast RNA polymerase I and molecular weight standards (Pharmacia) were used as molecular weight markers.
RESULTS
One of the two conserved lysines of domain H is labeled by derivative in
To map the active site of yeast RNA polymerase II, the enzyme was first cross-linked to a nucleotide derivative and then labeled by allowing phosphodiester bond formation with [or 32 P]UTP in the presence of DNA. A series of chemical cleavage reactions in combination with microsequence analysis allowed the localization of the nucleotide-binding site within the B150 subunit (1). Derivative III (Scheme 1) labeled the C-terminal part of the B150 subunit, between Asn946 and Met999. Five lysyl residues at positions 962, 965, 972, 979 and 987 are potential targets of the affinity reagent in this region (Fig. IB) . To identify the labeled Scheme 1.
Ade vm
Ada lysyl residues, each lysine was changed individually to arginine by site directed mutagenesis.
The effect of each mutation on yeast viability was tested by using the plasmid shuffling method described by Mann et al. (14) (see Materials and Mediods). Yeast cells transformed with plasmids pLS151 (K962R), pLS152 (K965R) or pLS153 (K972R) could loose the resident plasmid pRP214 that encodes the wild type B150 subunit, and grew normally. In contrast, the strains transformed with plasmids pLS147 (K979R) or pLS129 (K987R) were unable to loose the resident plasmid, indicating that the K979R and K987R mutations were lethal. Nevertheless, none of these two mutations was dominant since the growth of a strain carrying one of these plasmids in the presence of pRP214 was indistinguable from that of a control strain carrying pLSl 14 and pRP214 (both carrying a wild type RPB2 gene).
To determine the effect of the three non lethal K -R mutations on affinity labeling of RNA polymerase n, the enzyme from wildtype and each of the three mutant strains was purified and subjected to affinity labeling. Figure 2 shows the labeling of RNA polymerase II from wild-type strain (lane 1) or mutant strains carrying a K -R mutation at position 962 (lane 2), 965 (lane 3), or 972 (lane 4). All three mutated B150 subunits were labeled. If a unique lysine is the target site of the affinity reagent, this result indicates that one of the other two lysines, either K979 or K987 is labeled. However, it was not excluded that the affinity reagent could react productively with alternative lysyl residues. Therefore, the triple mutant was made (K962K965K972RRR). Remarkably, the transformants grew normally in the absence of the wild type gene. The enzyme carrying this triple mutation was purified and subjected to affinity labeling with derivative IH. Figure 2 Qane 5) shows that the B150 subunit of this enzyme is labeled. This result demonstrates that at least one of the other two lysines, K979 or K987, must be the target site for the affinity reagent.
Derivative Vm labels domains H and I
Exhaustive CNBr cleavage of the B150 subunit labeled with derivative VIII suggested that, in addition to domain H, another domain of the B150 subunit was labeled (1) . When E.coli RNA polymerase was modified with derivative VIE, two lysines located in the conserved domain I were found to be potential labeling sites (K1234 and K1242) (2) . In yeast, domain I contains a unique lysine (Kl 102)(equivalent to lysine 1242 in the E.coli ft subunit, Fig. IB) . Therefore, by analogy with the results obtained with the E.coli enzyme, we hypothesized that lysine 1102 was the target of derivative VIII in domain I. When lysine 1102 was changed to arginine, the resulting mutant strain grew like the wild type strain. RNA polymerase II from the mutant strain was purified and subjected to affinity labeling with derivative VIII. Subunit B150 was labeled with derivative VIE, as expected, since derivative VIII can also label domain H (Fig 3) . To determine if K1102 was the target of derivative VIII in domain I, the labeled B150 subunit was subjected to the single hit cleavage procedure designed by Grachev et al. (2) . We selected hydroxylamine as cleavage reagent since one of the four cleavage sites present in the B150 sequence is located between domains H and I (N1074-G1075) (Fig. 1 A) .The predicted pattern of labeled bands obtained when B150 is cleaved in single hit conditions indicates that when both domains H and I are labeled, the smallest peptide has a calculated molecular weight of 17.2 kDa whereas when only domain H is labeled, the smallest peptide has a calculated molecular weight of 30 kDa (Fig.3) . Indeed, with wild-type RNA polymerase, the radioactive bands observed corresponded to the band pattern predicted if both domains H and I were labeled. In particular, a band of about 17 kDa was clearly observed (Fig.3, lane 2) . On the other hand, this band was not present in the pattern from the enzyme carrying the Kl 102R mutation, even after overexposure of the autoradiogram (Fig.3, lane 4) , and the smallest labeled peptide has a molecular weight of 30 kDa as expected. Since the 17.2 kDa peptide was not labeled in the mutant enzyme, K1102 must be the unique target residue of derivative VIE in domain I.
DISCUSSION
The active site of yeast RNA polymerases was studied by affinity labeling with nucleotide derivatives (7) . The present work extends previous mapping data that identified the labeled domain in the C-terminal part of the /3-like subunit of yeast RNA polymerase II, between Asn947 and Met999 (1) .
In this conserved region, the five lysyl residues that are potential targets of the reagents were mutagenized to arginine. Lysines 962, 965 and 972 can be mutated individually or simultaneously without affecting cell growth. This result indicates that these three lysines are not essential for the catalytic activity of the enzyme. RNA polymerase II purified from the single mutants and from the triple mutant can still be affinity labeled by derivative IE and therefore at least one of the two lysines K979 or K987 is a target site of derivative IE. These two conserved lysyl residues are potentially labeled by affinity reagents IB and VIE in the /3-like RNA polymerase subunits from Sulfolobus acidocaldarius (2) and Methanobacteriwn thermoautotrophicum (18) . However, in E.coli, lysyl residue 1073 of the RNA polymerase j3 subunit corresponding to Lys987 in B150 subunit is not labeled by derivative IE (2) . Therefore, residue Lys979 is the most likely target for affinity reagent El. The importance of Lys979 is stressed by the results of Kaslev et al. (19) and Mustaev et al. (20) with E.coli RNA polymerase. Mutation of the lysyl residue 1065 of the ft subunit, homologous to lysyl residue 979 in the B150 subunit, leads to a lethal phenotype as in yeast. The mutational substitution of K1065 -R1065 did not inactivate the catalytic function of the E.coli enzyme but inhibited the transition from the initiation to the elongation stage of transcription (19) . Whether or not the homologous mutation in the yeast RNA polymerase leads to the same effect needs to be investigated. The K1065R mutation in the E.coli j3 subunit and the corresponding K979R mutation in the B150 subunit of yeast is lethal in both cases, but is dominant only in the former (19) . However, this dominant phenotype in E. coli could be due to the overproduction of the mutant /3 subunit. This was not the case in yeast where the mutant protein was controled by its own promoter on a centromeric plasmid.
The labeled lysyl residue, whether it is K979 or K987, is conserved and is essential for cell viability, indicating that it must play an important role, either in the structure of the enzyme or in the catalytic process. Its location in the active site suggests a functional role. To be labeled, RNA polymerase must be able to synthesize at least one phosphodiester bond. Hence the labeled residue is probably not directly involved in the formation of phosphodiester bonds since its modification would prevent affinity labeling via UMP incorporation. It is possible that the labeled lysine is involved in the elongation process or that it interacts with the RNA or the template.
Derivative VEI can label two different domains in B150 subunit, one of which is probably domain H (1). Derivative VIII was shown to label the conserved domain I of the bacterial (3 subunit and therefore we suspected domain I to be the second labeled domain. The pattern of labeled bands obtained after single-hit cleavage by hydroxylamine of the B150 subunit supports the prediction that both domains H and I are labeled (Fig.3) . These results are in agreement with those obtained with E.coli RNA polymerase. It has been demonstrated recently that derivative VIII labels domain H in addition to domain I (A.A.
Mustaev, personal communication).
By in vitro mutagenesis, we demonstrated that lysine 1102 is the unique target site of derivative VIE in domain I of the B150 subunit. Lysine 1102 is not essential in yeast RNA polymerase II or can be functionally replaced by arginine. It is conserved in all the second largest RNA polymerase subunits sequenced so far, except in Methanobacterium thermoautotrophicum where it is replaced by an arginine (Fig. IB) .The results obtained with both derivatives strongly suggest that the active site has a similar structure in E. colt and yeast enzymes, with domains H and I being in close proximity and both contributing to the active site.
The importance of domains H and I is further illustrated by the functional studies of Kashlev et al. (19) and Mustaev et al. (20) on E.coli RNA polymerase reconstituted in vitro with /3 subunits mutated either at K1065 (domain H) or HI273 (domain I). These studies demonstrated that the assembly of the mutant enzymes is not affected in vitro. The catalytic function of the RNA polymerase is not affected but the transition from the initiation to the elongation phase is inhibited. The function of these residues in the elongation process is not clear. They may be directly involved in binding of the nascent RNA or the ternary complex could be unstable with the mutant polymerases. Similar studies on the yeast enzyme would be of great interest but require the in vitro reconstitution of the enzyme which has not yet been achieved.
